JP Morgan Chase
LEGN icon

JP Morgan Chase’s Legend Biotech LEGN Stock Holding History

JP Morgan Chase’s Portfolio LEGN Stock Details LEGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$22.5M Buy
766,364
+478,261
+166% +$12.9M ﹤0.01% 2124
2026
Q1 		$4.99M Sell
288,103
-657,591
-70% -$12.5M ﹤0.01% 3297
2025
Q4 		$20.6M Buy
945,694
+636,090
+205% +$18.2M ﹤0.01% 2044
2025
Q3 		$10.1M Buy
309,604
+5,283
+2% +$195K ﹤0.01% 2709
2025
Q2 		$10.8M Sell
304,321
-14,622
-5% -$474K ﹤0.01% 2483
2025
Q1 		$10.8M Sell
318,943
-679,073
-68% -$24.4M ﹤0.01% 2475
2024
Q4 		$32.5M Buy
998,016
+634,990
+175% +$26.3M ﹤0.01% 1602
2024
Q3 		$17.7M Buy
363,026
+7,078
+2% +$377K ﹤0.01% 2105
2024
Q2 		$15.8M Sell
355,948
-41,251
-10% -$1.9M ﹤0.01% 2050
2024
Q1 		$22.3M Sell
397,199
-91,927
-19% -$5.54M ﹤0.01% 1806
2023
Q4 		$29.4M Buy
489,126
+37,301
+8% +$2.36M ﹤0.01% 1547
2023
Q3 		$30.3M Sell
451,825
-123,417
-21% -$8.57M ﹤0.01% 1372
2023
Q2 		$39.7M Buy
575,242
+19,226
+3% +$1.26M ﹤0.01% 1225
2023
Q1 		$26.8M Buy
556,016
+83,615
+18% +$4.09M ﹤0.01% 1459
2022
Q4 		$23.6M Sell
472,401
-42,333
-8% -$2.05M ﹤0.01% 1542
2022
Q3 		$21M Buy
514,734
+38,354
+8% +$1.8M ﹤0.01% 1549
2022
Q2 		$26.2M Buy
476,380
+70,979
+18% +$3M ﹤0.01% 1410
2022
Q1 		$14.7M Buy
405,401
+157,330
+63% +$6.22M ﹤0.01% 2027
2021
Q4 		$11.6M Buy
248,071
+150,159
+153% +$7.62M ﹤0.01% 2322
2021
Q3 		$4.95M Buy
97,912
+26,103
+36% +$1.09M ﹤0.01% 3032
2021
Q2 		$2.95M Buy
71,809
+6,727
+10% +$229K ﹤0.01% 3499
2021
Q1 		$1.89M Buy
65,082
+24,519
+60% +$669K ﹤0.01% 3766
2020
Q4 		$1.14M Buy
40,563
+2,916
+8% +$83.9K ﹤0.01% 3866
2020
Q3 		$1.16M Buy
37,647
+32,647
+653% +$1.1M ﹤0.01% 3561
2020
Q2 		$213K Buy
+5,000
New +$195K ﹤0.01% 4227

Other funds holding LEGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return

JP Morgan Chase's LEGN Position: Q2 2026 in Review

JP Morgan Chase increased its Legend Biotech (LEGN) stake by 166% in Q2 2026, buying an estimated $12.9M and bringing the position to 766,364 shares worth $22.5M. The position accounts for ﹤0.01% of the portfolio, ranked #2124.

JP Morgan Chase first reported a position in LEGN in Q2 2020 and has held it in 25 quarters since. The position peaked at $39.7M in Q2 2023. 219 funds tracked by Wall St. Rank hold LEGN as of Q2 2026.

  • JP Morgan Chase held 766,364 shares of Legend Biotech worth $22.5M as of Q2 2026.
  • JP Morgan Chase bought 478,261 Legend Biotech shares in Q2 2026, an estimated $12.9M.
  • Legend Biotech made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #2124 holding.
  • JP Morgan Chase first reported a position in Legend Biotech in Q2 2020 and has held it in 25 quarters since.
  • JP Morgan Chase's Legend Biotech position peaked at $39.7M in Q2 2023.
  • 219 funds tracked by Wall St. Rank held Legend Biotech as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.